Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced innovative cancer therapies like olverembatinib and lisaftoclax, both approved in China and currently in global Phase III trials. This accolade highlights the company's impact on global pharmaceutical innovation and its commitment to addressing unmet medical needs in cancer treatment. The company continues to expand its global development efforts and partnerships to bring new therapies to patients worldwide.
Vanguard introduced the 0-3 Month Treasury Bill ETF (VBIL) to compete with iShares' established SGOV ETF, both offering exposure to short-term U.S. Treasury bills. While Vanguard typically offers lower fees, VBIL's expense ratio is not yet clearly di...
Janet Kerr, a director at La-Z-Boy, has sold 3,653 shares of the company, generating $116,000 from the transaction. This sale could indicate a personal financial decision or portfolio adjustment, but it may also attract investor attention regarding i...
On Wednesday, the Financials and Materials sectors of the S&P 500 dropped by 1.62% and 0.73%, respectively, pushing both into oversold territory. This brings the total number of oversold sectors in the S&P 500 to seven out of eleven, the highest sinc...
Shares of TJGC Group Limited jumped nearly 54% after announcing plans to expand into AI hardware, led by new leadership in electronics manufacturing. Forward Industries rose 24% following an updated acquisition proposal for SkyAI, offering a 50% prem...
Ximen Mining Corp announced a private placement to raise up to $350,000 to support ongoing operations at its Kenville Gold Mine in British Columbia. The funds will serve as bridge capital while the company negotiates non-dilutive financing to develop...
